Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2017 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of the company's repeatable business escalating. We need to look for management's own words conveying that deals, orders, etc., are individually bigger now than before. Scanning the transcript: Management discusses originations, portfolio, etc. They mention high gross origination in Q4, but that's volume. They talk about larger transactions like Northern Oil and iHeart, but those are specific deals. They mention that they can underwrite larger commitments due to platform. But do they say that the average size of new deals is stepping up versus their own past? They mention that in Q4 they had highest gross origination since inception, but that's total volume, not unit size. They also mention that they have been able to underwrite larger commitments, but that's about capability, not necessarily that they are landing larger deals now as a pattern. They also discuss that they are focusing on lower middle market or larger companies, but that's not necessarily a progression. They mention that they have been able to do larger deals like iHeart and Northern Oil, but those are exceptional. They don't say that the typical deal size is increasing. They also mention that they are being selective and that repayments outpaced fundings in 2017, so net funding was small. They talk about maintaining discipline. The question asks: "does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago?" I don't see any explicit statement about that. They talk about origination volume, but not about average deal size increasing. They mention that they have a platform that allows them to underwrite larger commitments, but that's not the same as saying they are actually landing larger deals now. They also mention that they are being selective and that they are not growing the portfolio much. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.